Series D financing
Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies
Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials
Star Therapeutics Raises $125M as Bleeding Disorder Therapy Enters Phase III
Star Therapeutics; Series D financing; bleeding disorders; VGA039; Phase III clinical trial; biotech funding; rare diseases; antibody therapy
Big Pharma-Backed MapLight Plots IPO to Advance Neuro Pipeline
MapLight Therapeutics; IPO; neuro pipeline; Alzheimer’s disease psychosis; schizophrenia; M1/M4 muscarinic agonist; Series D financing; Morgan Stanley; biopharmaceutical; clinical trials
Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio
Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors
Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M
Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships
Neptune Medical Secures $97M in Funding, Launches Jupiter Endovascular Subsidiary
Neptune Medical, Jupiter Endovascular, GI robotics, endovascular technology, Series D financing, medical device innovation, healthcare technology